THE CLINICAL TRIAL TO STUDY THE EFFECT OF THE DRUG SHANMUGA CHOORANAM IN PATIENTS HAVING GASTRIC REGURGITATION

EVALUATION OF SHANMUGA CHOORANAM FOR URAGARI VATHAM(GASTRO OESOPHAGEAL REFLUX DISEASE)-AN OPEN CLINICAL STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016563

Enrollment

Registered

2018-12-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K92- Other diseases of digestive system

Interventions

Intervention1: SHANMUGA CHOORANAM: SHANMUGA CHOORANAM IS ADMINISTRATTED ORALLY AT THE DOSE OF 5gOD ALONG WITH GHEE FOR 48 DAYS Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: LOSS OF APPETITE DYSPHAGIA HEART BURN DUE TO INDIGESTION REGURGITATION

Exclusion criteria

Exclusion criteria: HIATUS HERNIA CHOLELITHIASIS PYLORIC STENOSIS ESOPHAGEAL CARCINOMA HELICOBACTER PYLORI ESOPHAGEAL CARCINOMA PREGNANT WOMEN

Design outcomes

Primary

Measure	Time frame
OUTCOME IS MAINLY ASSESSED BY REDUCTION IN CLINICAL SYMPTOMS AND BY COMPARING THE INVESTIGATIONAL PARAMETERS BEFORE AND AFTER TREATMENTTimepoint: OUTCOME IS MAINLY ASSESSED BY REDUCTION IN CLINICAL SYMPTOMS AND BY COMPARING THE INVESTIGATIONAL PARAMETERS BEFORE AND AFTER TREATMENT	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR YAMUNA R

GOVERNMENT SIDDHA MEDICAL COLLEGE ARUMBAKKAM CHENNAI

chittu758@gmail.com9444177230

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026